Journal of pain research · 2026
Long-Acting versus Short-Acting Opioids and Opioid-Related Disorders in Chronic Non-Cancer Pain: A Claims Data Analysis in Germany.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Brinkmöller Sabrina, Poß-Doering Regina, Straßner Cornelia, Laux Gunter
Аннотация
BACKGROUND: Chronic non-cancer pain is common in primary care and may be managed with long-term opioid therapy. The German guideline "Long-term Use of Opioids for Chronic Non-Cancer Pain" provides recommendations for such treatment. The role of opioid formulation (long-acting vs. short-acting) and the association with opioid-related disorders remains underexplored. This study aims to explore associations between opioid formulation and opioid-related disorders in patients with chronic non-cancer pain receiving long-term opioid therapy in German general practices.
METHODS: We conducted a retrospective cross-sectional claims data analysis using data from one statutory health insurer in Baden-Württemberg (AOK), Germany, for the year 2021. The analysis included patients aged ≥18 years who received at least one oral or transdermal opioid prescription in all four quarters. Exclusion criteria were malignant diseases or palliative care. The outcome was opioid-related disorder (ICD-10 category F11.-). Multivariable logistic regression analyses were performed to identify predictors.
RESULTS: Multiple models were calculated. The main model included a total of 34,205 patients. The mean age was 70 years, and 65% were female. Overall, 3.1% of patients were diagnosed with an opioid-related disorder. Weak opioids were most frequently prescribed. Long-acting opioids predominated. Higher odds of opioid-related disorders were observed in patients with substance use disorders involving such as sedatives (OR = 5.6, 95% CI: 4.48-7.01) or alcohol (OR = 2.2, 95% CI: 1.82-2.66). Short-acting opioids (OR = 2.0, 95% CI: 1.53-2.48) and combined long- and short-acting therapy (OR = 3.5, 95% CI: 2.38-5.00) were associated with higher odds of opioid-related disorders compared with long-acting opioids (all p <0.001).
CONCLUSION: The results suggest that short-acting opioids, either alone or as part of combination therapy, may be more strongly associated with opioid-related disorders in patients with chronic non-cancer pain and long-term opioid therapy than long-acting opioids alone. Further research is needed to clarify these relationships and their underlying causes.
METHODS: We conducted a retrospective cross-sectional claims data analysis using data from one statutory health insurer in Baden-Württemberg (AOK), Germany, for the year 2021. The analysis included patients aged ≥18 years who received at least one oral or transdermal opioid prescription in all four quarters. Exclusion criteria were malignant diseases or palliative care. The outcome was opioid-related disorder (ICD-10 category F11.-). Multivariable logistic regression analyses were performed to identify predictors.
RESULTS: Multiple models were calculated. The main model included a total of 34,205 patients. The mean age was 70 years, and 65% were female. Overall, 3.1% of patients were diagnosed with an opioid-related disorder. Weak opioids were most frequently prescribed. Long-acting opioids predominated. Higher odds of opioid-related disorders were observed in patients with substance use disorders involving such as sedatives (OR = 5.6, 95% CI: 4.48-7.01) or alcohol (OR = 2.2, 95% CI: 1.82-2.66). Short-acting opioids (OR = 2.0, 95% CI: 1.53-2.48) and combined long- and short-acting therapy (OR = 3.5, 95% CI: 2.38-5.00) were associated with higher odds of opioid-related disorders compared with long-acting opioids (all p <0.001).
CONCLUSION: The results suggest that short-acting opioids, either alone or as part of combination therapy, may be more strongly associated with opioid-related disorders in patients with chronic non-cancer pain and long-term opioid therapy than long-acting opioids alone. Further research is needed to clarify these relationships and their underlying causes.